NeoGenomics, Inc. (NEO)

US — Healthcare Sector
Peers: XGN  MDXH  STXS  ACRS  QTRX  SGMT  SMTI  ARCT  HUMA  TKNO 

Automate Your Wheel Strategy on NEO

With Tiblio's Option Bot, you can configure your own wheel strategy including NEO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NEO
  • Rev/Share 27.7196
  • Book/Share 36.5923
  • PB 0.3668
  • Debt/Equity 0.4895
  • CurrentRatio 3.908
  • ROIC -0.0945

 

  • MktCap 307065084.0
  • FreeCF/Share -0.6664
  • PFCF -18.0107
  • PE -2.7101
  • Debt/Assets 0.2985
  • DivYield 0
  • ROE -0.1303

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade NEO BTIG Research Buy Neutral -- -- July 30, 2025
Downgrade NEO William Blair Outperform Market Perform -- -- July 29, 2025
Initiation NEO Guggenheim -- Neutral -- -- May 15, 2025
Downgrade NEO Leerink Partners Outperform Market Perform -- $9 April 30, 2025
Downgrade NEO The Benchmark Company Buy Hold -- -- Jan. 13, 2025
Initiation NEO Jefferies -- Buy -- $22 Dec. 10, 2024

News

NeoGenomics, Inc (NEO) Q4 2024 Earnings Call Transcript
NEO
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Neutral

NeoGenomics, Inc (NASDAQ:NEO ) Q4 2024 Earnings Conference Call February 18, 2025 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations and ESG Chris Smith - Chief Executive Officer Warren Stone - Chief Commercial Officer Andrew Lukowiak - Chief Innovation Officer Jeffrey Sherman - Chief Financial Officer Kareem Saad - Head, Strategy and Transformation Nate Montgomery - Vice President, Medical Services Conference Call Participants Andrew Brackman - William Blair Puneet Souda - SVB Leerink Jack Slevin - Jefferies Mason Carrico - Stephens Tejas Savant - Morgan Stanley Vivian Bais - BTIG Prashant Kota - Goldman Sachs Dan …

Read More
image for news NeoGenomics, Inc (NEO) Q4 2024 Earnings Call Transcript

About NeoGenomics, Inc. (NEO)

  • IPO Date 2004-03-16
  • Website https://www.neogenomics.com
  • Industry Medical - Diagnostics & Research
  • CEO Anthony P. Zook
  • Employees 2200
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.